Decentralized Visits in Rare Disease Studies

Learn how ProPharma Group helped implement and execute decentralized visits for a pediatric rare disease study.

The COVID-19 pandemic caused major disruption to many clinical trials and the participants receiving treatment. The risk of exposure for pediatric rare disease patients and their families was particularly challenging and stressful. Reduced travel options compounded by the risk for exposure during travel or at the Site, affected the entire family. 


Read more about how ProPharma Group worked with the sponsor to implement and execute decentralized visits so that patients could continue their study as planned.

Case Study

Share

Infographic

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Webinar

Free Webinar: Effective FDA Engagement

FDA faces challenges (like new technology) and new review models (like real world evidence) that stretch agency standards and practices. At the same time, imperatives like product safety and efficacy...

Infographic

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma Group offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma Group’s Compliance and Quality team completed the...